Aspirin dosage and thromboxane synthesis in patients with vascular disease

Pharmacotherapy

Volumn 23, Issue 5, 2003, Pages 579-584

  Hart, Robert G ^a   Leonard, Anne D ^a   Talbert, Robert L ^a,b   Pearce, Lesly A ^f   Cornell, Elaine ^c   Bovill, Edwin ^d   Feinberg, William M ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c Colchester Research Laboratory ^*  (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f Univ of Texas Health Science Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CREATININE; THROMBOXANE; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFORMED CONSENT; MALE; OPEN STUDY; OUTPATIENT DEPARTMENT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; URINE LEVEL; VASCULAR DISEASE;

AGED; ASPIRIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; THROMBOXANES; VASCULAR DISEASES;

EID: 0038370082     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.5.579.32206     Document Type: Article

References (14)

1. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119(suppl):39s-63.
2. 2 formation in the human circulation. Proc Natl Acad Sci USA 1986;83:5861-5.
3. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
4. 2 and prostacyclin. Stroke 1992;23:1400-3.
5. 2 in African American stroke patients. Stroke 2002;33:57-60.
6. Dippel DW, van Kooten F, Mehecivic A, Li SC, Leebeek FW, Koudstaal PJ. What is the lowest dose of aspirin for maximum suppression of thromboxane synthesis? Cerebrovasc Dis 2002;13(suppl 3):65.
7. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin: the stroke prevention in atrial fibrillation III study. JAMA 1998;279:1273-7.
8. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
9. van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DW, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999;30:546-9.
10. 2 in human plasma and urine. Biochim Biophys Acta 1987;918:293-7.
11. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and highdose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial: ASA and carotid endarterectomy (ACE) trial collaborators. Lancet 1999;353:2179-84.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
13. Farrel B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
14. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6.